Overview and Scope
mTOR inhibitors refer to a class of drugs that inhibits the mTOR (mammalian/mechanistic target of rapamycin) protein, which aids in regulating cell division. The activity of mTOR is to stop the proliferation of cancer cells and prevent the development of new cells required for tumor growth.
Sizing and Forecast
The mtor inhibitors market size has grown strongly in recent years. It will grow from $7.11 billion in 2023 to $7.52 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to oncology treatment advancements, renal cell carcinoma treatment, transplantation medicine, clinical research and drug development, immunosuppressive applications..
The mtor inhibitors market size is expected to see strong growth in the next few years. It will grow to $9.3 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to expanding oncology indications, advancements in precision medicine, rising transplantation cases, chronic disease management, increasing geriatric population.. Major trends in the forecast period include exploration of neuroprotective effects, utilization in transplant medicine, rising interest in metabolic disorders, collaborations for drug development, global health initiatives for rare diseases..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report
Segmentation & Regional Insights
The mtor inhibitors market covered in this report is segmented –
1) By Product Type: Rapamune, Afinitor, Torisel, Zortress, Other Product Types
2) By Indication: Oncology, Immunosuppressant, Organ Transplantation, Other Indications
3) By Route of Administration: Oral, Intravenous
4) By Application: Tumor Treatment, Kidney Transplant, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the mTOR inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mtor inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10860&type=smp
Major Driver Impacting Market Growth
The rise in the prevalence of kidney diseases is expected to propel the growth of the mTOR inhibitors market going forward. Kidney disease refers to a condition that causes the organs to gradually deteriorate and lose their ability to function. mTOR inhibitors are used in the treatment of various kidney illnesses. Immunosuppressive treatments, including mTOR inhibitors such as sirolimus and everolimus are used to prevent renal allograft rejection. As the prevalence of kidney diseases continues to rise globally, the demand for mTOR inhibitors is increasing. For instance, in April 2022, according to the International Society of Nephrology, a US-based global professional association, there are 843.6 million people worldwide who are affected by stages 1 to 5 of kidney diseases. Over 800 million people globally or 10% of the overall population suffer from chronic renal disease, a degenerative ailment. Therefore, the rise in the prevalence of kidney diseases will propel the growth of the mTOR inhibitors market.
Key Industry Players
Major companies operating in the mTOR inhibitors market report are Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, LC Laboratories, Exelixis Inc., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Accord Healthcare Inc., Par Pharmaceutical, AbbVie Inc., GlaxoSmithKline PLC, Biocon Limited, Alkem Laboratories Ltd., Gland Pharma Ltd., Apotex Inc., Glenmark Pharmaceuticals Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co. Inc., AmpliPhi Biosciences Corporation, Melinta Therapeutics Inc., Aduro Biotech Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics PLC, Paratek Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation
The mtor inhibitors market report table of contents includes:
1. Executive Summary
2. mTOR Inhibitors Market Characteristics
3. mTOR Inhibitors Market Trends And Strategies
4. mTOR Inhibitors Market – Macro Economic Scenario
5. Global mTOR Inhibitors Market Size and Growth
.
.
.
31. Global mTOR Inhibitors Market Competitive Benchmarking
32. Global mTOR Inhibitors Market Competitive Dashboard
33. Key Mergers And Acquisitions In The mTOR Inhibitors Market
34. mTOR Inhibitors Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
